ABBREVIATIONS
INTERPRETATION
Patients from South Asian and deprived backgrounds had earlier LOA.
Genetic disease modifiers are likely to be implicated, but social and cultural factors influence access to treatment.
Duchenne muscular dystrophy (DMD) is an X-linked disorder with progressive muscle weakness arising as a result of mutations in the dystrophin gene. 1 Active supportive care to manage cardiac, respiratory, and orthopaedic complications has been shown to improve length and quality of life, 2 and International Standards of Care guidelines represent consensus on these standards. 3, 4 Corticosteroid treatment is known to confer benefit in most children with DMD, by prolonging ambulation and maintaining respiratory function. 5, 6 It has long been recognized that there is variation in the severity of disease, with affected males in natural history cohorts losing ambulation between 6 years and 12 years of age. 7, 8 Recently, genetic modifiers of disease course have been identified, [9] [10] [11] which may vary in incidence in different genetic populations. 12 In our neuromuscular clinic population -serving a diverse multi-ethnic population with high levels of deprivation -we noted an apparently more severe clinical course in males of South Asian ethnic origin and a tendency to be more likely to refuse or defer steroid therapy. We explored these potentially modifiable factors in our clinic population.
METHOD Patients
In this longitudinal cohort study we identified all children diagnosed with DMD in the 10 years from 1 Jan 2005 until 31 Dec 2014. We collected the following information for each child: age at diagnosis, ethnicity, 13 presence of family history of DMD, age at which steroids offered, age at which steroids commenced, reason for delay in starting steroids if applicable, age at which steroids stopped, reason why steroids stopped if applicable, whether English was spoken by parents, age at loss of ambulation (LOA). Using the patient's postcode at the time of diagnosis, we identified the lower layer super output area (a census area) from the Office for National Statistics database and then identified the Townsend score for this area to give a deprivation index for the patient. 14 
Steroid treatment
Glucocorticoid treatment is recommended in the International Standards of Care for DMD, 3, 4 and these guidelines have been accredited by the National Institute for Health and Clinical Excellence. 15 Within the UK, the NorthStar clinical network hosts the database for collecting data on standardized assessments and steroid use in males with DMD, following this National Institute for Health and Clinical Excellence-accredited guideline. 16 The 17 centres that are part of the NorthStar clinical network follow the agreed protocol of care for the use of steroids in DMD; this provides the standard for audit. Treatment is started optimally when the child is at the plateau of ability and before the decline phase, usually at 4 to 6 years of age. Immunity to varicella zoster is determined before steroid treatment is started, and if the child is not immune then immunization is given. The dose of steroid is reduced or stopped if there are intolerable sideeffects or if treatment is judged ineffective (parental view and continued deterioration in functional assessment, particularly the NorthStar ambulatory assessment). Steroids may be discontinued at loss of ambulation if the balance of benefit versus side-effects is unacceptable or may be continued to aid preservation of upper limb strength and respiratory function. 17 
Analysis
Comparisons of outcome (loss of ambulation) and steroid use were made, both between the major ethnic groups (white British vs South Asian) and by a measure of deprivation (the top 20% socio-economically [Townsend decile 1 & 2] vs the bottom 20% [Townsend decile group 9 & 10] ). Ages are presented as months for accurate statistical analysis. Kaplan-Meier survival analysis ('survival' defined as continued ability to ambulate) was used to determine probabilities over time of LOA for each group. To account for the children still ambulant at the end of the study, their age at 30 Apr 2016 was plotted as a censored result. Logrank test was used to evaluate comparisons between ethnic and socio-economic groups.
Ethics
This study was approved as a registered audit (no. 2958) with Heart of England Foundation Trust governance department.
RESULTS Patients
Seventy-one children from 68 families were newly diagnosed with DMD in this 10-year period. Sixty-seven were diagnosed in Birmingham, while four were diagnosed elsewhere then moved to the West Midlands. No child died during the study period. Two moved away during the study period, both of white British heritage; one diagnosed at 52 months (4y 4mo) and moved at 53 months (4y 5mo); the other diagnosed at 19 months (1y 7mo) and moved at 48 months (4y). Complete data were therefore available on 69 patients whose ethnic heritage was white British 33, South Asian (Indian, Pakistani, Bangladeshi) 23, white European three, mixed heritage seven, other Asian two, and black African one. Twenty-one patients had parents who did not speak English as their first language. We included data for the two lost to follow-up in the KaplanMeier analysis at the point they were last seen in clinic. As they had not yet been offered steroids, their data are not included in the analysis of steroid use.
All patients have a genetically confirmed diagnosis of DMD, with an identified dystrophin gene mutation (43 deletions; eight duplications; 17 point mutations of which seven are nonsense mutations; one pericentric inversion).
The mean current age at April 2016 was 9 years and 10 months (range 4y 5mo-17y 10mo).
For 15 children, there was a family history of confirmed DMD. Two males presented with symptoms at 26 months and 60 months and with a known family history. For six males, the family history was not known to their parents or was not disclosed at the time of diagnosis.
The age at diagnosis ranged from 20 days to 98 months. Two were diagnosed soon after birth because of a known family history. Three were screened (at 34mo, 39mo, and 40mo) after their siblings were diagnosed (two of the siblings are included in this cohort; the third was diagnosed before the study period so is not included). If these five are excluded, then the range of age at diagnosis was 5 months to 98 months with a mean of 45.7 months (3y 10mo); mean age of diagnosis for males of white British ethnicity was 42.1 months (3y 6mo; range 14-86mo) and for those of South Asian ethnicity 50.2 months (4y 2mo; range 5-98mo).
Twenty-four males lost ambulation during the study period and 45 are still walking, at age 4 years 5 months to 15 years 9 months. For those who lost ambulation, the mean age of LOA was 111 months (9y 3mo). Of those who reached age 9 years during the study period, 30 per cent had LOA. This mean age of LOA includes only those who lost ambulation during the study period. When we plotted survival curves for the total cohort including those who were still ambulant as censored results, estimated mean age of LOA for the study population as a whole was 128.9 months (10y 9mo; 95% CI 116.3-141.4mo) and estimated median age 120 months (10y; 95% CI 113.7-126.3mo). The median age of LOA for the UK NorthStar cohort was 144 months (12y) for intermittent steroids and 174 months (14y 6mo) for daily steroids. 16 What this paper adds • The most deprived children with DMD lose ambulation earlier than the least deprived.
• Children from South Asian backgrounds are more likely to decline or stop steroids.
For the total study population, the mean age at starting steroids was 74.8 months; 12 per cent who were offered steroids declined treatment. Of those who started steroids, 30 per cent had a delay commencing treatment of over 6 months, 26 per cent stopped steroid treatment. The age at starting steroids is comparable with the UK NorthStar data, where the mean starting age was 76.8 months (6y 5mo). 16 Outcome and steroid treatment by ethnic and socioeconomic groups Table I shows comparisons between the 33 males of white British ethnicity and 23 of South Asian ethnicity, and for the whole cohort. The current age and median Townsend decile were similar between the two groups, although those of South Asian heritage were in general more deprived, with 47 per cent being in the lower 20 per cent of the population for deprivation. Parents of all those with white British heritage spoke English as a first language compared with 39 per cent of parents with South Asian heritage. Age at starting steroids was similar between the two groups (73.4mo, standard deviation [SD] 9.2mo vs 75.0mo, SD 10.3mo). Of both groups, 28 per cent had a delay in starting steroids of more than 6 months from when first offered. This was either because of the need to complete varicella immunization before starting steroids or because of parental wishes. Four (18%) of the South Asian ethnicity parents declined steroids compared with three (9%) of the white British ethnicity parents. The largest difference in steroid use between the two groups was in the proportion stopping steroids, with 44 per cent (eight of 18 who had steroids) of the South Asian ethnic group stopping steroids compared with 17 per cent (five of 29 who had steroids) of the white British ethnic group. Reasons for stopping steroids were parental wishes, unacceptable steroid side-effects (including weight gain, behavioural disturbance, obstructive sleep apnoea), ineffectiveness (parental perception or decline in NorthStar ambulatory assessment despite steroid treatment), or loss of ambulation. Parental wish was recorded where this was the dominant factor. Some parents were not keen for their child to receive steroid treatment, and despite consenting to start treatment would request stopping after an interval. This was often in combination with subjective perception of side-effects (most commonly exacerbation of pre-existing behavioural problems).
In the South Asian ethnic group, none of the four who declined steroids spoke English as a first language. Those who delayed or stopped steroids were less likely to use English as a first language than those who did not delay and were still taking (38% vs 50%).
During the study period, 10 out of 33 males of white British heritage lost ambulation at a mean age of 117.8 months (9y 10mo) and 10 out of 23 males of South Asian heritage lost ambulation at a mean age of 105.8 months (8y 10mo). Figure 1 shows Kaplan-Meier To look at this another way, only 11 per cent (2 out of 19) of children with white British heritage who had reached their 9th birthday by the end of the study period had lost ambulation, whereas 54 per cent (7 out of 13) of children with South Asian heritage who had reached their 9th birthday had lost ambulation. Table II Two of six children in the top 20 per cent group had LOA in the study period and eight of 18 of the bottom 20 per cent group. For those who had lost ambulation, the mean age at LOA was 130.0 months (10y 10mo) for the top 20 per cent and 102.5 months (8y 6mo) in the bottom 20 per cent. Kaplan-Meier plots (Fig. 2) showed a significant difference in time to LOA between the two groups, with a log-rank test score of 0.035 (p<0.05).
Of the children who had reached age 9 years during the study period, none of the top socio-economic 20 per cent had LOA by this age, compared with 55 per cent of those in the bottom 20 per cent.
Males of South Asian heritage and those in the bottom socio-economic 20 per cent socio-economically appear to have worse outcome with regards to age at LOA. However, as those of South Asian heritage tended to be more deprived, we explored this as a potential confounding factor by comparing those of white British heritage and those of South Asian heritage in the bottom 20 per cent socio-economic group. There were six patients of white British heritage and 10 of South Asian heritage in the bottom socio-economic 20 per cent. The South Asian ethnic group were younger currently (mean age 8y 6mo compared with 10y 6mo). More patients of South Asian heritage declined steroids and more had a delay of over 6 months in starting or stopped taking steroids. The outcome for those of South Asian heritage was worse in this group: the mean age at LOA for patients with white British heritage was 112 months (9y 4mo; SD 6.16mo) compared with 95.25 months (7y 11mo; SD 3.34) for patients with South Asian heritage; in this group, of the children who reached age 9 years during the study period, 20 per cent of patients of white British heritage had LOA compared with 80 per cent of patients of South Asian heritage. We performed Cox hazard analysis to assess the effect of ethnicity, socio-economic status (higher 50% vs lower 50%), age at diagnosis, refusing steroids, and not speaking English as a first language independently on age at LOA. Most of the hazard ratios were not statistically significant (probably because of the small cohort size) except for not speaking English as a first language, which had a hazard ratio for earlier LOA of 10.5 (95% CI 1.1-101; p=0.041).
DISCUSSION
It is likely that genetic modifiers, known to influence disease course in DMD 12 are more prevalent in the different ethnic groups. We do not have this information for our patients. The LTBP4 genotype is known to be protective and more prevalent in the Caucasian population. 12 Polymorphisms in SPP1 also have been reported to be associated with variations in age at LOA, 9,18 although these results have not been confirmed in other studies. 11 An SPP1 polymorphism appears to be a biomarker of steroid responsiveness. 12 We were interested to see whether cultural and socioeconomic factors in our patient population influenced their outcome and hence whether there might be modifiable factors. Overall, patients from a South Asian background and patients from deprived backgrounds had LOA at an earlier age, with significant differences in their time to LOA. There have been previous indications that DMD is associated with social deprivation, 19 but our study additionally explores outcome variation in DMD. The poorer outcome for patients of South Asian heritage was still evident even when deprivation was taken into account: those with South Asian heritage tended to come from more deprived backgrounds, but when we compared those with white British heritage and those with South Asian heritage only in Townsend groups 9 and 10, there remained a difference in outcome, with 20 per cent of patients with white British heritage losing ambulation by the age of 9 years compared with 80 per cent of those with South Asian heritage. The estimated median age of LOA is lower in our cohort than for the whole NorthStar data, despite similar age of steroid initiation. We speculate that this may relate to there being a higher proportion of children of South Asian heritage or from deprived communities in this cohort. Data on ethnicity are not available for the whole NorthStar population.
Corticosteroid therapy is the only treatment known to ameliorate progression of the disease, 5 so its use is a pivotal part of the International Standards of Care guidelines. We found variation in steroid use, with patients of South Asian heritage being more likely to decline, defer, or stop steroid treatment. When we looked at the reasons patients gave for stopping steroids, those in the South Asian ethnic group were much more likely to cite parental wishes and steroids being ineffective than those in the white British ethnic group. While genetic modifiers may be contributing to steroid responsiveness, 12 there may also be influences of differing expectations and illness beliefs affecting steroid use. It is notable that of those parents of South Asian heritage who declined steroids, none spoke English as a first language and those who delayed or stopped steroid treatment were also less likely to speak English. Not speaking English as a first language was the only variable in our analysis associated with a statistically significant increased risk of earlier LOA. This is despite the use of interpreters in our clinics to aid discussion of steroid use and support from neuromuscular care advisors who run parent groups patients who were still ambulatory at the end of the study so LOA time is unknown but is sometime after the censored line.
for families with young children with DMD. We wonder whether specific peer support groups modelled on the Awaaz forum in West Yorkshire would additionally help this group of families (www.musculardystrophyuk.org/getthe-right-care-and-support/people-and-places-to-help-you/ peer-support/awaaz). A US study indicated that in their population, Hispanics and non-Hispanic black patients were less likely to receive steroids or more likely to delay steroid initiation compared with white patients. 20 This study did not explore whether deprivation was a contributory factor.
Steroid use is unlikely to account fully for the difference seen in outcomes, as when we compared the top 20 per cent socio-economic group with the bottom 20 per cent, we found that the top 20 per cent group were more likely to decline or defer steroid use, yet none of the top 20 per cent socio-economic group had loss of ambulation by 9 years of age, compared with 55 per cent of the bottom 20 per cent socio-economic group. This suggests that other factors such as access to other therapies or services may be playing a role in the better outcome in the more affluent patients. Perhaps patients of South Asian heritage are less likely to access other services or therapies which may also affect their outcome. This is a small observational study looking at our patient population. As there are small numbers it is difficult to draw definitive conclusions about differences between the groups. However, from the results of our study, it seems that children with DMD from South Asian backgrounds are not accessing recommended treatment with steroids in a timely manner, or are more likely to stop treatment early compared with their white British peers. This is associated with a difference in their outcome with regards to loss of ambulation, although genetic modifiers and access to other services are likely also to play a role in this difference. Understanding some of the cultural influences and illness beliefs which impact on these choices may help improve access to supportive care for these children, which may in turn improve their outcome.
From the point of view of overall service delivery, it is important to be aware of these factors when measuring and monitoring outcome measures between clinical services with different populations by ethnic and socio-economic mix.
